• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
WU Jinwen,ZHANG Ying,TIAN Jilai.Role of IL-6/gp130 in rheumatoid arthritis: Study progress from mechanism to clinical transformation[J].Journal Of Pharmaceutical Research,2019,38(7):412-418[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3302times   Download 3193次 QR Code for this article
Scan with your phone!
IL-6/gp130在类风湿性关节炎疾病中的作用:从机制到临床转化进展
吴锦雯1,张莹2,田吉来1
Font:Larger+|Default|Smaller-
(1.南京中医药大学医学与生命科学学院药理学系,江苏 南京 210023;2.南京大学医学院附属鼓楼医院风湿免疫科,江苏 南京 210008)
摘要:
白细胞介素-6(IL-6)参与慢性炎症的发生、自身抗体的产生以及血管通透性改变等过程,是类风湿性关节炎发作期间最高表达的炎性介质之一,成为药物治疗的靶点。不同来源的白细胞介素-6可以通过与白细胞介素-6Rα和gp130结合,经经典信号转导或转移信号转导或聚类信号转导模式,介导JAK-STAT、ERK-MAPK和PI3K-AKT 3种途径的细胞内信号转导,引起炎症发生。针对白细胞介素-6/gp130的靶向药物逐步被开发,但是仍然存在着诸多不良反应和副作用,靶向给药途径或局部给药途径治疗类风湿性关节炎被看好。本文总结了以白细胞介素-6及其受体为靶标的类风湿性关节炎治疗药物研发与使用情况,讨论了新型给药系统在类风湿性关节炎治疗研究中的优势,期望能为治疗类风湿性关节炎药物的研发提供新的思路。
关键词:  类风湿性关节炎  白细胞介素-6  gp130  靶向给药  纳米给药系统
DOI:10.13506/j.cnki.jpr.2019.07.010
基金项目:江苏省高等学校大学生创新创业训练计划项目(No.201910312075Y);江苏省自然科学基金(No.BK20180121)
Role of IL-6/gp130 in rheumatoid arthritis: Study progress from mechanism to clinical transformation
WU Jinwen1,ZHANG Ying2,TIAN Jilai1
(1.Department of Pharmacology, School of Medicine and Life Sciences,Nanjing University of Chinese Medicine,Nanjing 210023,China;2.Department of Rheumatology,Affiliated Drum Tower Hospital,School of Medicine,Nanjing University,Nanjing 210008,China)
Abstract:
Interleukin-6 (IL-6) is involved in development of chronic inflammation,autoantibody production and vascular permeability changes. It is one of the most highly expressed inflammatory mediators during the onset of rheumatoid arthritis and has become a target for drug therapy. Different sources of IL-6 can mediate JAK-STAT, ERK-MAPK and PI3K-AKT through classic-signaling or trans-signaling or cluster-signaling transduction pathway by binding to IL-6Rα and gp130. Intracellular signal transduction causes inflammation. Targeted drugs against IL-6/gp130 have been gradually developed, but there are still many adverse reactions and side effects. Thus targeted drug delivery or local treatment of rheumatoid arthritis are favored. This article summarized the current development and application of drugs targeting IL-6 and its receptors in the treatment of rheumatoid arthritis, discussed the advantages of new drug delivery systems in the treatment of rheumatoid arthritis, expecting to provide new ideas for developing new drugs for treatment of rheumatoid arthritis.
Key words:  Rheumatoid arthritis  Interleukin-6  gp130  Targeted drug delivery  Nano drug delivery system
Today's Visits:468    Total Visits:2383167
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.